Engage Therapeutics

December 3, 2018

Engage Therapeutics Successfully Completes Open Label Portion of Phase 2b StATES Study and Begins Enrollment in Double-Blind Placebo-Controlled Portion

On December, 3, 2018, Engage Therapeutics announced at the American Epilepsy Society’s Annual Meeting the successful completion of the open label portion of the StATES (Staccato […]
October 22, 2018

Engage Therapeutics board member is named one of TIME’s “The Health Care 50” for epilepsy research

Engage Therapeutics board member is named one of TIME’s “The Health Care 50” for epilepsy research: Health Care 50 | Time.com
September 14, 2018

Interview with Greg Mayes of Engage Therapeutics

Greg Mayes is the president, CEO, and founder of Engage Therapeutics, founded in 2017 to clinically develop and progress a product called staccato alprazolam, which had […]
September 14, 2018

What The After Party Gets Right About Epilepsy

“When an aspiring rapper goes viral for all the wrong reasons, he thinks his career is over. But when his best friend gets them into a […]